Company profile: Intellia Therapeutics
1.1 - Company Overview
Company description
- Provider of genome editing therapies developing curative gene-editing treatments, including CRISPR-based candidates NTLA-2001 for transthyretin amyloidosis via single intravenous in vivo gene editing and NTLA-2002 for hereditary angioedema by editing KLKB1 to reduce kallikrein activity. Offers in vivo CRISPR platform using lipid nanoparticles and ex vivo platform engineering T cells for oncological and immunological diseases.
Products and services
- In Vivo CRISPR Platform: Architects a lipid nanoparticle-based system delivering CRISPR/Cas9 directly into the body to edit disease-causing genes and treat genetic diseases with precise in vivo targeting
- NTLA-2001: Engineers an in vivo CRISPR therapy for transthyretin amyloidosis, performing gene editing via a single intravenous infusion to treat the disease by directly modifying pathogenic genes
- NTLA-2002: Produces a CRISPR-based investigational therapy for hereditary angioedema, editing the KLKB1 gene to reduce kallikrein activity and prevent angioedema attacks through targeted gene modulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Intellia Therapeutics
Genos
HQ: United States
Website
- Description: Provider of a revolutionary approach that brings DNA ownership into your hands and keeps genomic data actionable by connecting you with trusted partners to learn about yourself, help your community, and drive research to better human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genos company profile →
Veritas Genetics
HQ: United States
Website
- Description: Provider of a genetic testing platform that detects a wider range of gene variations than typical next-generation sequencing and offers screening for hereditary breast and ovarian cancer risk, empowering people to live healthier and longer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veritas Genetics company profile →
Kailos Genetics
HQ: United States
Website
- Description: Provider of personalized health information and clinical genetic assays on a patented technology platform, offering Expedioâ„¢ Hereditary Cancer Risk Testing, Inspexionâ„¢ Pharmacogenetic Testing, Kailos Laboratory Services, Reagents and Sequencing Solutions, and Assure Sentinelâ„¢ COVID-19 Testing, leveraging next generation sequencing and CAP-accredited laboratory support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kailos Genetics company profile →
Applied Microarrays
HQ: United States
Website
- Description: Provider of design, optimization and manufacturing services for DNA and protein biosensors and other microarrays on glass, plastic and semiconductors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied Microarrays company profile →
Exosome Diagnostics
HQ: United States
Website
- Description: Provider of biofluid-based molecular diagnostics leveraging exosome-derived nucleic acids for personalized medicine, including the urine-based, non-invasive ExoDx Prostate Test that provides a risk score for high-grade prostate cancer using genomic biomarkers from urine exosomes, plus at-home and in-office collection kits, EMR integrations, and availability for U.S. Veterans, supporting patient stratification and disease monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exosome Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Intellia Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Intellia Therapeutics
2.2 - Growth funds investing in similar companies to Intellia Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Intellia Therapeutics
4.2 - Public trading comparable groups for Intellia Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →